<DOC>
	<DOCNO>NCT00334022</DOCNO>
	<brief_summary>In order well understand source ( ) mechanism ( ) HIV persistence potentially lead suppression HIV viral reservoir , propose examine effect co-administration enfuvirtide , entry inhibitor HIV , diminution size viral reservoir infect individual receive effective antiviral therapy extend period time ( &gt; 5 year ) .</brief_summary>
	<brief_title>Fuzeon Viral Decay Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>1 . Patient must HIV infect 2 . Patient must &gt; 18 year old 3 . Patient must take standard combination antiretroviral therapy 23 NRTIs 12 PIs NNRTIs least five year 4 . Patient must viral load &lt; 50 copies/mL ( use standard available method detection ) entire time standard combination antiretroviral therapy except initial fall viral load 5 . Patient must CD4 count 400 cells/mm3 last 3 month 6 . Female patient must agree use two method birth control abstinence period study 7 . Patient sign full informed consent 1 . Patient would difficulty participate trial due nonadherence substance abuse 2 . Patient take mono dual antiretroviral therapy 3 . Patient viral load &gt; 50 copies/mL antiretroviral regimen 4 . Patient follow abnormal laboratory test result screen : Hemaglobin &lt; 100 g/L Neutrophil count &lt; 750 cells/uL Platelet count &lt; 50,000 cells/L AST ALT &gt; 5X upper limit normal Creatinine &gt; 250 umol/L 5 . Patient malignancy 6 . Patient significant underlying disease ( nonHIV ) might impinge upon disease progression death 7 . Patient active AIDSdefining illness past six month 8 . Patients pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Fuzeon</keyword>
	<keyword>Viral Decay</keyword>
</DOC>